|
|
15 Skyline Drive
Hawthorne, NY 10532 USA
phone:914-347-4300
fax:914-347-4560
|
|
| Symbol |
ACOR |
| Exchange |
Nasdaq |
| Founded |
1995 |
| Employees |
65 |
|
|
| www.acorda.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Develops therapies to restore neurological function |
|
| Management |
| Ron Cohen, M.D., President and Chief Executive Officer; R. Blight, Ph.D., Chief Scientific Officer; Anthony O. Caggiano, M.D., Ph.D., Vice President, Preclinical Development; Denise Duca, Ed.M., Sr. Vice President, Human Resources; Herbert Raymond Henney III, Pharm.D. Vice President, Medical Affairs |
| |
|
|
|
|
|
|
| |
|
|
|
|
| Keywords |
| tizanidine hydrochloride, tizanidine, sclerosis, neurological function, spasticity |
|
|
|
|
|
|
| Description |
|
Acorda Therapeutics is a biotechnology company that develops and markets therapies to restore neurological function in people with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the nervous system. |
|
| Products / Services |
The company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members